BGLC BGLC
Company Profile ↓Company Overview
BGLC (BGLC) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.03.
Recent Developments
- Dec 2025 Revenue of $7.42M (-21.9% YoY); net profit $-2.98M.
- Trailing 12 Months Year-on-year growth — revenue -21.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -12.1%, profit CAGR -246.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -12.09% |
| 1 Year: | -21.93% |
Compounded Profit Growth
| 5 Years: | -246.15% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -76.81% |
| 6 Months: | -41.89% |
| 3 Months: | -24.51% |
| 1 Month: | -19.37% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -12.1% CAGR over 5 years.
- Earnings shrank at -246.2% CAGR over 5 years.
- Trading 76.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 111.30K | 91.62K | 28.09K | 21.64K | 24.17K | 3.07M | 1.10M | 3.09M | 3.45M | 3.09M | 3.58M | 3.03M | 2.49M | 2.58M | 2.38M | 2.57M | 2.55M | 2.38M | 1.97M | 2.63M | 2.14M | 2.26M | 2.54M | 22.84K |
| Gross Profit | -12.53K | 25.65K | 22.37K | 9.27K | 4.62K | 7.67K | 655.31K | 159.29K | 522.22K | 582.57K | 467.61K | 709.19K | 356.33K | 263.97K | 299.50K | 368.90K | 339.71K | 354.33K | 365.03K | 288.72K | 326.54K | 343.49K | 368.02K | 377.69K | -790 |
| Operating Income | - | -39.47K | -55.14K | -60.20K | -69.22K | -50.14K | 1.07M | -33.97K | 237.31K | 342.10K | 139.99K | 372.64K | 34.69K | -137.96K | -65.22K | -50.63K | -272.20K | -2.53M | -79.03K | 259.17K | -1.34M | -618.42K | -611.29K | -702.51K | -540.49K |
| Net Income | 271.86K | -39.47K | -88.96K | -61.47K | -70.40K | -22.03K | 1.07M | -35.84K | 234.46K | 338.74K | 28.26K | 295.32K | 17.07K | -138.66K | -77.40K | -69.07K | -259.25K | -2.61M | -103.76K | 199.10K | -1.35M | -623.33K | -616.17K | -708.99K | -543.58K |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.01 | 0.11 | -0.75 | -0.35 | -0.34 | -0.40 | -0.23 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.47K | 8.20K | 10.44K | 12.14K | 12.56K | 14.88K | 14.49K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 212.33K | 126.95K | 11.39M | - | 10.93M | 9.77M | 9.51M | 7.42M |
| Cost of Revenue | - | - | - | - | 9.67M | 8.44M | 8.22M | 6.34M |
| Gross Profit | 28.77K | 55.89K | 1.72M | - | 1.26M | 1.33M | 1.29M | 1.09M |
| Operating Expenses | - | - | - | - | 1.55M | 4.41M | 3.25M | 4.24M |
| Operating Income | 59.90K | -275.70K | 1.27M | - | -291.18K | -3.08M | -1.96M | -3.16M |
| EBITDA | - | - | - | - | -185.76K | -2.49M | -1.42M | -2.80M |
| Interest Expense | - | - | - | - | 12.48K | 13.93K | 21.15K | 19.54K |
| Pretax Income | - | - | - | - | -303.66K | -2.61M | -1.59M | -2.98M |
| Tax Provision | - | - | - | - | 52.31K | 21.53K | 3.49K | 0 |
| Net Income | 26.45K | -246.47K | 1.09M | - | -355.97K | -2.63M | -1.60M | -2.98M |
| Diluted EPS | - | - | - | - | -0.46 | -1.66 | -0.90 | -1.61 |
| R&D Expense | - | - | - | - | - | 54.98K | 47.51K | 50.67K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2018 | Dec 2018 | Dec 2019 | Jan 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.65M | 1.23M | - | 10.12M | 9.57M | 8.74M | 11.40M | 10.43M | 9.25M |
| Total Equity | 94.63K | 1.52M | 1.12M | 1.12M | 6.66M | 7.18M | 6.67M | 9.66M | 8.32M | 8.61M |
| Cash & Equivalents | - | 1.26M | 859.08K | - | 2.79M | 2.12M | - | - | 2.89M | 2.49M |
| Total Liabilities | - | 130.31K | 108.87K | - | 3.45M | 2.39M | 2.08M | 1.74M | 2.11M | 637.86K |
| Current Liabilities | - | 62.89K | 51.57K | - | 3.37M | 2.33M | 2.00M | 1.63M | 1.95M | 520.96K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -274.08K | -217.27K | 552.68K | 9.16K | 551.82K | -1.82M | -2.09M | -1.84M |
| Investing Cash Flow | -51.70K | -12.82K | 1.32M | -490.57K | -450.50K | -1.79M | 418.20K | 944.75K |
| Financing Cash Flow | 742.94K | -180.81K | -4.95K | -28.22K | 108.17K | 6.27M | 3.98K | 298.84K |
| Capital Expenditure | 39.62K | -12.82K | -421.62K | -3.16K | -0 | -149.40K | -226.99K | -36.97K |
| Free Cash Flow | -234.46K | -230.09K | 131.06K | 6.00K | 551.82K | -1.97M | -2.32M | -1.88M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 13.5% | 44.0% | 15.1% | - | 11.5% | 13.6% | 13.6% | 14.6% |
| Operating Margin % | 28.2% | -217.2% | 11.2% | - | -2.7% | -31.5% | -20.6% | -42.5% |
| Net Margin % | 12.5% | -194.1% | 9.6% | - | -3.3% | -26.9% | -16.8% | -40.2% |
| ROE % | 1.7% | -22.0% | 16.4% | - | -5.3% | -27.2% | -19.2% | -34.6% |
| ROCE % | 3.8% | -23.4% | 18.9% | - | -4.3% | -31.5% | -23.1% | -36.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BGLC
BioNexus Gene Lab Corp (BGLC) director reports holding 0 common shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQZS1RcVdiUjA3d3hoOGFtR0dsbkxJM3lVV3NyMWljbU9Pb2psUW1BOXlTVllnbDkzcnRHZWctMW5PYmUxVnFBYkFDbEZQdGVhem1WWEhMeGRuXzZTYmhZWmtqbV84YXRyNFJVVXNqOFpmZ3RoNkZJTzV1WVlnQUNwMXNFZFlXaklsRzA5NE…
BioNexus Gene Lab (BGLC) director files Form 3 with zero shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNVWR5THR4ZWVMa0U4WE9MQ1Z3R2drYVNWQ3ozN0ZNSG9LODBKbVp5YWQxR2tZX3hiWWVSOVZjUWpUNjE5emZzdkNSbmlkNTlOLXpxMldyVDdKMlc0Rmw4RlZ3WjlIbkZ5YVBiSFNCSUJ4WHhkMjFLU1FGOFhqQll0MEh4SWdyaUtBb2xZVT…
BioNexus Gene Lab Corp Revenue Breakdown – NASDAQ:BGLC - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBlOXEwcl8tejh6bURPODBDODRqN3Z0X2ltTUJkSlpDdHlqWHhLM1lsXy12MEI4U3ZrMWtWbFlKdzV6cjlQd3pUZF9hXzVETU9tQWRlN1pMdHhKYV8zaVJTNGRqV1JpMVNmTzVjZmhXcS1wVnNyeU9V?oc=5" target="_blank">BioNexu…
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxOZG5SbG1KejQ3RzBqQndsQmRYSUhPeDlFa0QtZzI4ekphcmtrTXhCbHlBUkhYVUM1WHdXNms5T09oanRNYmF5dFduTlVCWTBhWnZBZWNkS0lTN0tvNDR4Zi1xUWdxSlVhX3dfblJ2Zk1EZlNibllwM3E5dUpZemthNg?oc=5" target="_…
BioNexus Gene Lab Corp (BGLC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9MejJld0Q5cXplREdLUllxckhiNkZ1UWVtQ2Ntd0F6RWtQbnB5VklJOWhqZlJqbHIyNi1kUm1KdEdteGhuSFRVSG00TjBqeTktdmQ3NUV3LXpDTkE0dW9qeVFuTUpvYWJQY1c5TmVn?oc=5" target="_blank">BioNexus Gene Lab C…
Avoiding Lag: Real-Time Signals in (BGLC) Movement - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOd1RYRThOalMxSVNMTnlxWEE3NnF3d010Q0kxd3JPdVBhdlhJajd1SjJkMjZVNEg0cjdURlhmWkpMYzVFM0xaVERMY3Q5eWUtOXFkamdRVGRNY2NFbi0tYmpXQkdkWHg3Mi16Ym1kV2tDVXZ5WnBEalU5RkZZUTFRczlfQ2RMZnNxZ0hBR0…
BGLC — Frequently Asked Questions
What is the current share price of BGLC?
As of 2026-08-05 17:25 PDT, BGLC trades at $1.54 on NASDAQ/NYSE. Its 52-week range is $1.32 to $6.64.
What is the P/E ratio of BGLC?
BGLC trades at a trailing price-to-earnings (P/E) ratio of -0.96.
What is the return on equity (ROE) of BGLC?
BGLC has a return on equity (ROE) of -34.64%. Its return on capital employed (ROCE) is -36.17%.
Is BGLC a good stock to buy?
This page provides a data-driven analysis of BGLC, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.